DiADeM is a tool to support GPs in diagnosing dementia for people living with advanced dementia in a care home setting. It has been developed by the Yorkshire and Humber Dementia Strategic Clinical ...

Alzheimer's disease (AD), the most common cause of dementia, is a progressive neurodegenerative disorder affecting millions of people worldwide. AD has a multifactorial origin, resulting from an ...

A third agent in the class, donanemab (Kisunla), gained FDA approval ... microglia to ingest and eliminate fibrillar amyloid-beta (Aβ), according to a review in BioDrugs. "Each of the approved ...

But in just the past year and a half, two anti-amyloid drugs—lecanemab (Leqembi) and donanemab (Kisunla)—that can slow the progression of early Alzheimer’s disease have been approved in the US.

The study found that two recently approved medications, lecanemab and donanemab, could potentially extend independence in daily activities by approximately 10 months for patients in the early stages ...

Patients who took lecanemab extended their time at home for an additional 10 months, while donanemab enabled them to live independently for eight more months, according to a WashU press release.

Understanding how long a person can stay independent may help some people and clinicians determine if trying a drug such as lecanemab or donanemab is worth the risks and high prices. The study ...

New research shows that lecanemab and donanemab can slow cognitive decline ... samples for amyloid beta (Aβ) and tau protein assessment. All participants underwent clinical and cognitive ...